Profile data is unavailable for this security.
About the company
Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. Its segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. The Company also provides tech-enabled training and compliance solutions for clinical trial investigators and site staff.
- Revenue in USD (TTM)66.98m
- Net income in USD9.65m
- Incorporated1996
- Employees192.00
- LocationSimulations Plus Inc42505 10Th Street WestLANCASTER 93534-7059United StatesUSA
- Phone+1 (661) 723-7723
- Fax+1 (661) 723-5524
- Websitehttps://www.simulations-plus.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Varex Imaging Corp | 832.70m | 34.20m | 444.99m | 2.30k | 23.79 | 0.7649 | 6.54 | 0.5344 | 0.4574 | 0.4574 | 16.46 | 14.22 | 0.6758 | 1.95 | 5.28 | 346,958.30 | 2.82 | 0.9913 | 3.33 | 1.18 | 32.16 | 31.70 | 4.17 | 1.36 | 1.89 | 2.00 | 0.4271 | -- | 3.96 | 2.93 | 59.08 | 18.88 | 0.2924 | -- |
| MaxCyte Inc | 45.44m | -35.43m | 457.49m | 143.00 | -- | 2.06 | -- | 10.07 | -0.3408 | -0.3408 | 0.437 | 2.11 | 0.1739 | 0.4741 | 7.46 | 317,762.90 | -13.56 | -13.18 | -14.25 | -14.33 | 88.43 | 88.79 | -77.97 | -62.96 | 13.40 | -- | 0.00 | -- | -6.72 | 19.89 | -60.89 | -- | 39.13 | -- |
| ZimVie Inc | 453.38m | -54.86m | 467.62m | 2.60k | -- | 1.19 | -- | 1.03 | -2.04 | -13.27 | 16.84 | 14.29 | 0.3858 | 1.12 | 3.80 | 174,378.50 | -4.67 | -- | -5.43 | -- | 63.11 | 65.51 | -12.10 | -8.73 | 1.43 | -0.3884 | 0.3737 | -- | -1.26 | -16.08 | -19.50 | -- | -23.70 | -- |
| Pacific Biosciences of California Inc | 188.87m | -400.38m | 555.96m | 796.00 | -- | 1.13 | -- | 2.94 | -1.50 | -1.50 | 0.7099 | 1.81 | 0.1125 | 2.05 | 6.69 | 237,275.10 | -23.85 | -16.19 | -26.63 | -17.81 | 26.01 | 37.35 | -211.99 | -136.21 | 7.14 | -22.46 | 0.6444 | -- | 56.29 | 20.59 | 2.39 | -- | 36.68 | -- |
| Surmodics Inc | 120.82m | -1.40m | 557.71m | 376.00 | -- | 4.76 | 76.26 | 4.62 | -0.0955 | -0.0955 | 8.55 | 8.28 | 0.6597 | 2.09 | 5.64 | 321,332.40 | -0.7638 | -1.85 | -0.8909 | -2.18 | 74.02 | 82.93 | -1.16 | -2.98 | 3.22 | -4.46 | 0.1999 | -- | 32.65 | 10.27 | 94.37 | -- | -27.02 | -- |
| Paragon 28 Inc | 235.44m | -59.07m | 574.51m | 430.00 | -- | 3.91 | -- | 2.44 | -0.7132 | -0.7132 | 2.84 | 1.76 | 0.7703 | 0.6049 | 6.63 | 547,539.60 | -19.33 | -- | -23.48 | -- | 76.67 | -- | -25.09 | -- | 1.70 | -5.30 | 0.4295 | -- | 19.30 | -- | 28.94 | -- | -- | -- |
| Quanterix Corp | 129.33m | -39.71m | 594.49m | 441.00 | -- | 1.77 | -- | 4.60 | -1.04 | -1.04 | 3.40 | 8.77 | 0.3078 | 2.37 | 4.60 | 293,265.30 | -9.45 | -15.96 | -10.30 | -17.66 | 57.42 | 52.79 | -30.71 | -53.79 | 8.99 | -- | 0.00 | -- | 15.96 | 26.60 | 66.56 | -- | 20.07 | -- |
| Orthofix Medical Inc | 771.65m | -120.49m | 611.73m | 1.63k | -- | 1.14 | -- | 0.7928 | -3.21 | -3.21 | 20.55 | 14.35 | 0.8654 | 1.17 | 6.49 | 472,245.40 | -13.51 | -8.88 | -16.22 | -10.96 | 67.18 | 72.37 | -15.62 | -9.28 | 1.13 | -4.94 | 0.2005 | -- | 62.06 | 10.51 | -666.60 | -- | 30.01 | -- |
| Iradimed Corp | 69.48m | 18.64m | 623.73m | 148.00 | 33.65 | 7.83 | 32.04 | 8.98 | 1.46 | 1.46 | 5.45 | 6.29 | 0.8109 | 1.55 | 6.03 | 469,485.30 | 21.76 | 13.16 | 23.85 | 14.58 | 77.21 | 76.55 | 26.83 | 21.46 | 8.25 | 144.05 | 0.00 | 68.13 | 23.00 | 16.59 | 34.02 | 22.22 | 97.77 | -- |
| AxoGen Inc | 173.48m | -16.54m | 642.98m | 426.00 | -- | 6.72 | -- | 3.71 | -0.3829 | -0.3829 | 4.01 | 2.18 | 0.9117 | 1.62 | 7.43 | 407,237.10 | -8.69 | -13.92 | -9.93 | -15.84 | 76.98 | 79.74 | -9.53 | -20.28 | 2.32 | -2.94 | 0.3297 | -- | 14.74 | 13.63 | 24.98 | -- | 17.70 | -- |
| Simulations Plus Inc | 66.98m | 9.65m | 645.45m | 192.00 | 68.05 | 3.57 | 45.64 | 9.64 | 0.474 | 0.474 | 3.29 | 9.04 | 0.3603 | -- | 5.57 | 348,843.80 | 5.19 | 7.20 | 5.49 | 7.61 | 72.53 | 77.61 | 14.40 | 21.29 | -- | -- | 0.00 | 45.70 | 10.52 | 14.96 | -20.20 | 6.02 | 12.91 | 0.8548 |
| SI-Bone Inc | 150.71m | -40.85m | 660.02m | 344.00 | -- | 3.99 | -- | 4.38 | -1.00 | -1.00 | 3.70 | 3.97 | 0.6586 | 1.54 | 6.67 | 438,107.60 | -17.85 | -27.88 | -19.57 | -30.94 | 77.69 | 85.03 | -27.10 | -51.09 | 8.12 | -- | 0.18 | -- | 30.52 | 20.19 | 29.25 | -- | 52.62 | -- |
| Mesa Laboratories Inc | 223.71m | -250.31m | 694.70m | 736.00 | -- | 4.61 | -- | 3.11 | -46.43 | -46.43 | 41.43 | 27.87 | 0.4131 | 2.51 | 6.29 | 303,956.50 | -46.23 | -9.20 | -50.62 | -9.88 | 62.27 | 60.60 | -111.89 | -28.33 | 1.37 | 1.33 | 0.5848 | -- | -1.32 | 15.95 | -27,438.28 | -- | 15.26 | 0.00 |
| Cytek Biosciences Inc | 197.71m | -17.56m | 695.66m | 645.00 | -- | 1.79 | -- | 3.52 | -0.1327 | -0.1327 | 1.49 | 2.96 | 0.392 | 1.54 | 4.19 | 292,470.40 | -3.48 | -- | -3.89 | -- | 54.97 | -- | -8.88 | -- | 6.38 | -- | 0.0083 | -- | 17.67 | -- | -571.58 | -- | -- | -- |
| Orthopediatrics Corp | 175.07m | -25.12m | 707.30m | 247.00 | -- | 1.91 | -- | 4.04 | -1.10 | -1.10 | 7.65 | 15.33 | 0.4045 | 0.4286 | 4.61 | 708,793.50 | -5.80 | -5.40 | -6.43 | -5.93 | 74.62 | 75.09 | -14.35 | -15.92 | 1.96 | -44.23 | 0.0261 | -- | 21.62 | 20.91 | -1,767.25 | -- | 28.29 | -- |
| Standard Biotools Inc | 136.30m | -164.66m | 783.14m | 534.00 | -- | 1.53 | -- | 5.75 | -0.9018 | -0.9018 | 0.6606 | 1.37 | 0.2561 | 2.25 | 5.73 | 255,243.50 | -22.29 | -28.17 | -26.55 | -33.60 | 46.67 | 51.58 | -87.05 | -74.85 | 3.53 | -- | 0.0974 | -- | 8.57 | -1.20 | 60.73 | -- | 50.06 | -- |
Data as of Sep 19 2024. Currency figures normalised to Simulations Plus Inc's reporting currency: US Dollar USD
44.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Jun 2024 | 2.27m | 11.35% |
| Conestoga Capital Advisors LLCas of 30 Jun 2024 | 2.26m | 11.31% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.11m | 5.53% |
| Ranger Investment Management LPas of 30 Jun 2024 | 835.73k | 4.18% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 611.35k | 3.06% |
| Geode Capital Management LLCas of 30 Jun 2024 | 429.69k | 2.15% |
| Ophir Asset Management Pty Ltd.as of 30 Jun 2024 | 424.62k | 2.12% |
| Dimensional Fund Advisors LPas of 30 Jun 2024 | 390.74k | 1.95% |
| Threadneedle Asset Management Ltd.as of 30 Jun 2024 | 308.10k | 1.54% |
| Wasatch Advisors LPas of 30 Jun 2024 | 294.82k | 1.47% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
